FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4223895978> ?p ?o ?g. }

• W4223895978 endingPage "695" @default.
• W4223895978 startingPage "683" @default.
• W4223895978 abstract "Although the use of PARP inhibitor has received considerable amount of attention in ovarian cancer, PARP inhibitor resistance still emerges with disease progression. PI3K/AKT pathway inhibitors have been proposed to synergize with PARP inhibition to slow tumor growth, but the exact molecular mechanisms are still elusive.Utilizing tumor samples from recurrent EOC patients with platinum resistance and prior PARP inhibitor use, Mini PDX and PDX models were established to study the anti-tumor effect of AKT inhibitor (LAE003) and LAE003/PARP inhibitor (Olaparib) in combination. Five ovarian cancer cell lines were treated with Olaparib or LAE003 or in combination in vitro. Cell viability and apoptosis rate were measured after the treatments. Combination index by the Chou-Talalay was used to evaluate in vitro combination effect of Olaparib and LAE003. The protein expression level of PARP1 and PAR was measured by Western blot in cell lines and by immunohistochemistry in PDX tumor tissues.Tumor cells from two out of five platinum-resistant ovarian cancer patients previously treated with PARP inhibitor were sensitive to AKT inhibition in Mini-PDX study. Inhibition of AKT further increased the response of tumor cells to Olaparib in a PDX model derived from a recurrent platinum-resistant ovarian cancer patient. Additive anti-proliferation effect of LAE003 and Olaparib was also observed in three ovarian cancer cell lines with high PARP1 protein level. Interestingly, mechanism study revealed that AKT inhibition decreased PARP enzyme activity as measured by PAR level and/or reduced PARP1 protein level in the tumor cell lines and PDX tumor tissues, which may explain the observed combined anti-tumor effect of LAE003 and Olaparib.Collectively, our results suggest that the combination of AKT inhibitor and PARP inhibitor could be a viable approach for clinical testing in recurrent ovarian cancer patients." @default.
• W4223895978 created "2022-04-19" @default.
• W4223895978 creator A5011610308 @default.
• W4223895978 creator A5013095342 @default.
• W4223895978 creator A5017100408 @default.
• W4223895978 creator A5022734035 @default.
• W4223895978 creator A5030505775 @default.
• W4223895978 creator A5031133786 @default.
• W4223895978 creator A5037677450 @default.
• W4223895978 creator A5053952657 @default.
• W4223895978 creator A5054901507 @default.
• W4223895978 creator A5079435230 @default.
• W4223895978 creator A5083773255 @default.
• W4223895978 creator A5090916655 @default.
• W4223895978 date "2022-04-13" @default.
• W4223895978 modified "2023-10-14" @default.
• W4223895978 title "An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer" @default.
• W4223895978 cites W1836682153 @default.
• W4223895978 cites W1898580708 @default.
• W4223895978 cites W1969043065 @default.
• W4223895978 cites W1973138129 @default.
• W4223895978 cites W1973268287 @default.
• W4223895978 cites W1997338647 @default.
• W4223895978 cites W2032665292 @default.
• W4223895978 cites W2057620850 @default.
• W4223895978 cites W2078168537 @default.
• W4223895978 cites W2096439168 @default.
• W4223895978 cites W2100525241 @default.
• W4223895978 cites W2147111123 @default.
• W4223895978 cites W2161817637 @default.
• W4223895978 cites W2162409477 @default.
• W4223895978 cites W2172261116 @default.
• W4223895978 cites W2199466904 @default.
• W4223895978 cites W241899038 @default.
• W4223895978 cites W2489000876 @default.
• W4223895978 cites W2528228811 @default.
• W4223895978 cites W2548423821 @default.
• W4223895978 cites W2557666746 @default.
• W4223895978 cites W2593067736 @default.
• W4223895978 cites W2609248852 @default.
• W4223895978 cites W2767593721 @default.
• W4223895978 cites W2873526615 @default.
• W4223895978 cites W2888002479 @default.
• W4223895978 cites W2890903471 @default.
• W4223895978 cites W2896250649 @default.
• W4223895978 cites W2896744886 @default.
• W4223895978 cites W2901666999 @default.
• W4223895978 cites W2903881613 @default.
• W4223895978 cites W2921991537 @default.
• W4223895978 cites W2923414225 @default.
• W4223895978 cites W2946007191 @default.
• W4223895978 cites W2975141952 @default.
• W4223895978 cites W3008619716 @default.
• W4223895978 cites W3015444296 @default.
• W4223895978 cites W3034800902 @default.
• W4223895978 cites W3036860998 @default.
• W4223895978 cites W3063162426 @default.
• W4223895978 cites W3086233365 @default.
• W4223895978 doi "https://doi.org/10.1007/s00280-022-04403-9" @default.
• W4223895978 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35419627" @default.
• W4223895978 hasPublicationYear "2022" @default.
• W4223895978 type Work @default.
• W4223895978 citedByCount "4" @default.
• W4223895978 countsByYear W42238959782022 @default.
• W4223895978 countsByYear W42238959782023 @default.
• W4223895978 crossrefType "journal-article" @default.
• W4223895978 hasAuthorship W4223895978A5011610308 @default.
• W4223895978 hasAuthorship W4223895978A5013095342 @default.
• W4223895978 hasAuthorship W4223895978A5017100408 @default.
• W4223895978 hasAuthorship W4223895978A5022734035 @default.
• W4223895978 hasAuthorship W4223895978A5030505775 @default.
• W4223895978 hasAuthorship W4223895978A5031133786 @default.
• W4223895978 hasAuthorship W4223895978A5037677450 @default.
• W4223895978 hasAuthorship W4223895978A5053952657 @default.
• W4223895978 hasAuthorship W4223895978A5054901507 @default.
• W4223895978 hasAuthorship W4223895978A5079435230 @default.
• W4223895978 hasAuthorship W4223895978A5083773255 @default.
• W4223895978 hasAuthorship W4223895978A5090916655 @default.
• W4223895978 hasBestOaLocation W42238959781 @default.
• W4223895978 hasConcept C121608353 @default.
• W4223895978 hasConcept C126322002 @default.
• W4223895978 hasConcept C181199279 @default.
• W4223895978 hasConcept C182979987 @default.
• W4223895978 hasConcept C190283241 @default.
• W4223895978 hasConcept C2778480876 @default.
• W4223895978 hasConcept C2779138821 @default.
• W4223895978 hasConcept C2779962180 @default.
• W4223895978 hasConcept C2780427987 @default.
• W4223895978 hasConcept C502942594 @default.
• W4223895978 hasConcept C55493867 @default.
• W4223895978 hasConcept C71924100 @default.
• W4223895978 hasConcept C75217442 @default.
• W4223895978 hasConcept C82381507 @default.
• W4223895978 hasConcept C86554907 @default.
• W4223895978 hasConcept C86803240 @default.
• W4223895978 hasConceptScore W4223895978C121608353 @default.
• W4223895978 hasConceptScore W4223895978C126322002 @default.
• W4223895978 hasConceptScore W4223895978C181199279 @default.

• next